- |||||||||| Symlin (pramlintide) / AstraZeneca, Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) () - May 18, 2020 - Abstract #ADA2020ADA_3011; On the last outpatient day, mean daily bolus doses were 4 U lower with ADO09 (-21%, p=0.05). Both treatments were well tolerated with more gastrointestinal adverse events (24 vs. 6) observed with ADO09, consistent with typical effect of PRAM.In conclusion, ADO09 significantly improved CGM metrics including TIR, weight control and bolus insulin needs vs. Novolog over 24 days of use.
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Study of Insulin Stability Impact on Pump Therapy: Test Model Development () - May 18, 2020 - Abstract #ADA2020ADA_1823; Preliminary findings from in-vitro and in-vivo test model development indicate that macrophage number, the inflammatory response, and device wear time were significantly impacted by loss of preservative and trace aggregates/particles. The new test methodology can further our understanding as to how to improve IS wear time.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Type 1 Diabetes: Real-World Insulin Injection Patterns () - May 18, 2020 - Abstract #ADA2020ADA_1800; These real-world data give a unique insight into the bolus and basal adherence of pediatric and adult patients with T1D. Furthermore, the results illustrate the flexibility needed for basal injections to enable optimal management of T1D.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements () - May 18, 2020 - Abstract #ADA2020ADA_1281; This post-hoc analysis of the 16-week onset 9 trial aimed to confirm this and explore efficacy and safety of FA vs. IAsp, both with insulin degludec, in bolus-experienced adults with T2D (duration ≥10 yrs) by insulin requirement...There was a trend towards lower rates of severe or blood glucose-confirmed hypoglycemia with higher insulin doses at meal test, with a benefit for FA vs. IAsp in the >20 U subgroup. Treatment difference (FA vs. IAsp) in change from baseline in PPG increments was unaffected by bolus insulin dose; however hypoglycemia risk may be lower with FA vs. IAsp in adults with long-standing T2D and high bolus insulin requirements.
- |||||||||| IDegLira (insulin degludec/liraglutide) / Novo Nordisk
Enrollment closed: IDegLira HIGH Trial (clinicaltrials.gov) - May 17, 2020 P3, N=140, Active, not recruiting, Recruiting --> Active, not recruiting
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: FIasp (clinicaltrials.gov) - Apr 30, 2020 P3, N=40, Completed, Recruiting --> Suspended Active, not recruiting --> Completed
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
Journal: Comparative Dose Accuracy of Durable and Patch Insulin Pumps Under Laboratory Conditions. (Pubmed Central) - Apr 26, 2020 Thirty-two OP and 15 MM were tested using insulin aspart at five different boluses (0.5, 1, 5, 10, and 15 international units [IU]) and three basal rates (0.2, 0.6, and 1.8 IU/h) at different time points during a 70 h investigation period...This study demonstrates low accuracy for basal rates and single bolus deliveries at low insulin doses for both pump models. Clinicians should be aware of this variability when initiating insulin pump therapy especially in insulin-sensitive patients with low insulin dose requirements.
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
Journal: Role of ultrafast-acting insulin analogues in the management of diabetes. (Pubmed Central) - Apr 14, 2020 This article reviews the clinical evidence supporting the use of RAIAs as part of a basal-bolus regimen in patients with diabetes, with a focus on new formulations whose pharmacological profiles more closely mimic the endogenous prandial insulin secretion pattern that is seen in individuals without diabetes. This review also provides a clinical perspective to help guide health care professionals in the use of RAIAs.
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
Review, Journal: Type 1 Diabetes in Pregnancy. (Pubmed Central) - Mar 29, 2020 Recent advances including Continuous Glucose Monitoring Systems, Continuous Subcutaneous Insulin Infusion, Closed Loop Devices and very Fast Acting Insulin Aspart analogs offer new possibilities to increase glucose time in target in selected, motivated patients, however their relative roles and indication for use require further elucidation. The importance of education cannot be overstated.
- |||||||||| Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Metastases: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) - Mar 24, 2020 P=N/A, N=75, Active, not recruiting, The importance of education cannot be overstated. Recruiting --> Active, not recruiting
- |||||||||| Replacing long-term continuous subcutaneous insulin infusion (CSII) in type 2 diabetics with insulin degludec and liraglutide (IdegLira) once a day usually results in an improved metabolic state (poster area 3) - Mar 22, 2020 - Abstract #DDG2020DDG_342;
Group of 8 T2D age 65 (49-77) years, diabetes duration 17.5 (12-28) years, BMI 36 (30.5-41.3) kg / m2, 4 men, 4 women, previous insulin pump therapy ( Pump Paradigm Veo 754, Medtronic, CA, USA, with insulin aspart, self-checks with glucometer Calla Wellion, Austria 2-5x / d) was at least 3 years... Treatment with IdegLira can significantly improve metabolism in T2D compared to CSII.
- |||||||||| Journal: Trends in Prices of Popular Brand-Name Prescription Drugs in the United States. (Pubmed Central) - Mar 3, 2020
Changes in prices paid were highly correlated with third-party estimates of changes in drug net prices (ρ = 0.55; P = 3.8 × 10-5), suggesting that the current rebate system, which incentivizes high list prices and greater reliance on rebates, increases overall costs. The growth of drug spending in the United States associated with government-protected market exclusivity is likely to continue; greater price transparency is warranted.
- |||||||||| Kixelle (insulin aspart biosimilar) / Viatris, Biocon
Trial completion: Mylan Insulin Aspart Study (clinicaltrials.gov) - Feb 28, 2020 P3, N=528, Completed, The growth of drug spending in the United States associated with government-protected market exclusivity is likely to continue; greater price transparency is warranted. Active, not recruiting --> Completed
- |||||||||| Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 18, 2020 P4, N=250, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed: FIasp (clinicaltrials.gov) - Feb 17, 2020 P3, N=40, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- |||||||||| Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Unusual Presentation of Diabetic Ketoacidosis Associated with Hypernatremia in Adult Patient (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1957; When there is marked osmotic diuresis, DKA may present with a normal or even elevated serum Na concentration, despite a markedly elevated serum BG. To best of our knowledge, this is the second case to report an unusual DKA presenting with hypernatremia in adult patient.
- |||||||||| Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
An Unusual and Enigmatic Etiology for Diabetic Ketoacidosis: Safety Needles (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1936; Therefore, appropriate administration must be taught to the patient, including perpendicular insertion of the needle into the subcutaneous tissue and ensuring a more firm surface by injecting into a lifted skin fold. Legislation in the US has been passed requiring safety-engineered devices when feasible.In situations where the safety-engineered devices can impair effectiveness or cause harm, alternative approaches can be utilized, including insulin syringes or self-administration of insulin along with safe work procedures (1).
- |||||||||| SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
Enrollment closed: GEMELLI X: Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Jan 27, 2020 P3, N=184, Active, not recruiting, Legislation in the US has been passed requiring safety-engineered devices when feasible.In situations where the safety-engineered devices can impair effectiveness or cause harm, alternative approaches can be utilized, including insulin syringes or self-administration of insulin along with safe work procedures (1). Recruiting --> Active, not recruiting
|